Cargando…

The impact of extended half-life versus conventional factor product on hemophilia caregiver burden

INTRODUCTION: Extended half-life factor products have reduced annualized bleeding rates in hemophilia patients. The impact of extended half-life versus conventional factor products on hemophilia caregiver burden has not been investigated. This study aimed to evaluate caregiver burden in extended hal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schwartz, Carolyn E., Powell, Victoria E., Su, Jun, Zhang, Jie, Eldar-Lissai, Adi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891570/ https://www.ncbi.nlm.nih.gov/pubmed/29392598 http://dx.doi.org/10.1007/s11136-018-1792-9

Ejemplares similares

Measuring hemophilia caregiver burden: validation of the Hemophilia Caregiver Impact measure
por: Schwartz, Carolyn E., et al.
Publicado: (2017)

Physical activity and bleeding outcomes among people with severe hemophilia on extended half‐life or conventional recombinant factors
por: Shrestha, Anshu, et al.
Publicado: (2020)

Longitudinal validity of the hemophilia caregiver impact measure
por: Schwartz, Carolyn E., et al.
Publicado: (2019)

Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B
por: Miguelino, Maricel G, et al.
Publicado: (2014)

Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia
por: Versloot, Olav, et al.
Publicado: (2022)

Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products
por: Tortella, Bartholomew J., et al.
Publicado: (2018)

Extended Half-Life Coagulation Factors: A New Era in the Management of Hemophilia Patients
por: Ar, Muhlis Cem, et al.
Publicado: (2019)

The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B
por: Sun, Haowei (Linda), et al.
Publicado: (2021)

Essential tremor patients experience significant burden beyond tremor: A systematic literature review
por: Gerbasi, Margaret E., et al.
Publicado: (2022)

Updating the Canadian Hemophilia Outcomes–Kids’ Life Assessment Tool (CHO‐KLAT) in the era of extended half‐life clotting factor concentrates
por: Price, Victoria E., et al.
Publicado: (2021)

Epidemiology of Pediatric Essential Tremor in the United States: A Systematic Literature Review from 2010 to 2020
por: Gerbasi, Margaret E., et al.
Publicado: (2022)

Extended half‐life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products
por: Teitel, Jerome, et al.
Publicado: (2021)

Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A
por: Coyle, T E, et al.
Publicado: (2014)

Comparison of extended to standard half-life recombinant factor VIII therapy in patients with hemophilia A on prophylactic therapy
por: McCall, Michael, et al.
Publicado: (2019)

Monitoring standard and extended half‐life products in hemophilia: Assay discrepancies for factor VIII and IX in pre‐ and postinfusion samples
por: Augustsson, Cecilia, et al.
Publicado: (2020)

In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients
por: Preijers, T., et al.
Publicado: (2021)

First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results
por: Königs, Christoph, et al.
Publicado: (2022)

Cost-Effectiveness of Brexanolone Versus Selective Serotonin Reuptake Inhibitors for the Treatment of Postpartum Depression in the United States
por: Eldar-Lissai, Adi, et al.
Publicado: (2020)

Using Matching-Adjusted Indirect Comparisons and Network Meta-analyses to Compare Efficacy of Brexanolone Injection with Selective Serotonin Reuptake Inhibitors for Treating Postpartum Depression
por: Cooper, Miranda C., et al.
Publicado: (2019)

Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A
por: Shah, Anita, et al.
Publicado: (2019)

Comparison of Real-World Dose and Consumption for Two Extended Half-Life Recombinant Factor VIII Products for the Treatment of Hemophilia A in the United States
por: Wu, Yanyu, et al.
Publicado: (2022)

Chimeric antibodies with extended half-life in ferrets
por: Nesspor, Thomas C, et al.
Publicado: (2014)

Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A
por: Solms, Alexander, et al.
Publicado: (2020)

The Half Life of Stress: Caregiver Stress Increases Next-Day Severity of Behavioral Symptoms of Dementia
por: Pickering, Carolyn, et al.
Publicado: (2020)

Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies
por: Peyvandi, Flora, et al.
Publicado: (2020)

Assessing the Performance of Extended Half-Life Coagulation Factor VIII, FC Fusion Protein by Using Chromogenic and One-Stage Assays in Saudi Hemophilia A Patients
por: Owaidah, Tarek M., et al.
Publicado: (2020)

Extended half-life factor IX prophylaxis up to every 21 days in hemophilia B: a longitudinal analysis of the efficacy and safety in selected adult patients
por: Pabinger, Ingrid, et al.
Publicado: (2023)

Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII
por: Kearney, Susan, et al.
Publicado: (2019)

Biodistribution of recombinant factor IX, extended half-life recombinant factor IX Fc fusion protein, and glycoPEGylated recombinant factor IX in hemophilia B mice
por: van der Flier, Arjan, et al.
Publicado: (2023)

Quality of Life in Caregivers of Patients Randomized to Standard- Versus Extended-Hours Hemodialysis
por: Nataatmadja, Melissa, et al.
Publicado: (2021)

Monoclonal Antibodies with Extended Half-Life to Prevent Covid-19
por: Abraham, Jonathan
Publicado: (2022)

The mediating effect of caregiver burden on the caregivers’ quality of life
por: Jeong, Yeon-Gyu, et al.
Publicado: (2015)

Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia
por: Thorat, Teja, et al.
Publicado: (2018)

Associations between commonly used patient-reported outcome tools in postpartum depression clinical practice and the Hamilton Rating Scale for Depression
por: Gerbasi, Margaret E., et al.
Publicado: (2020)

Brexanolone in Postpartum Depression: Post Hoc Analyses to Help Inform Clinical Decision-Making
por: Gerbasi, Margaret E., et al.
Publicado: (2021)

Successful Hemostasis with Extended Half-life Recombinant Factor VIII in Circumcision
por: Koç, Başak, et al.
Publicado: (2020)

Caregiver Burden and Quality of Life of Key Caregivers of Patients with Dementia
por: Srivastava, Garima, et al.
Publicado: (2016)

Clinical Predictors and Prediction Models for rFVIII-Fc Half Life in Real-World People with Severe Hemophilia A
por: Chang, Chia-Yau, et al.
Publicado: (2023)

Predicted effectiveness of vaccines and extended half-life monoclonal antibodies against RSV hospitalizations in children
por: Zheng, Zhe, et al.
Publicado: (2022)

Extending human IgG half-life using structure-guided design
por: Booth, Brian J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_67ljggd78uu5n8v1h44ls2fha0